One-year immunologic outcomes of lung transplantation utilizing hepatitis C-viremic donors.
infection and infectious agents
rejection: acute
viral: hepatitis C
Journal
Clinical transplantation
ISSN: 1399-0012
Titre abrégé: Clin Transplant
Pays: Denmark
ID NLM: 8710240
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
revised:
16
05
2022
received:
28
02
2022
accepted:
03
06
2022
pubmed:
12
6
2022
medline:
11
8
2022
entrez:
11
6
2022
Statut:
ppublish
Résumé
Little is known about the effects of hepatitis C viremia on immunologic outcomes in the era of direct-acting antivirals. We conducted a prospective, single-arm trial of lung transplantation from hepatitis C-infected donors into hepatitis C-naïve recipients (n = 21). Recipients were initiated on glecaprevir-pibrentasvir immediately post-transplant and were continued on therapy for a total of 8 weeks. A control group of recipients of hepatitis C-negative lungs were matched 1:1 on baseline variables (n = 21). The primary outcome was the frequency of acute cellular rejection over 1-year post-transplant. Treatment with glecaprevir-pibrentasvir was well tolerated and resulted in viremia clearance after a median of 16 days of therapy (IQR 10-24 days). At one year, there was no difference in incidence of acute cellular rejection (71.4% vs. 85.7%, P = .17) or rejection requiring treatment (33.3% vs. 57.1%, P = .12). Mean cumulative acute rejection scores were similar between groups (.46 [SD ± .53] vs. .52 [SD ± .37], P = .67). Receipt of HCV+ organs was not associated with acute rejection on unadjusted Cox regression analysis (HR .55, 95% CI .28-1.11, P = .09), or when adjusted for risk factors known to be associated with acute rejection (HR .57, 95% CI .27-1.21, P = .14). Utilization of hepatitis C infected lungs with immediate treatment leads to equivalent immunologic outcomes at 1 year.
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14749Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2019 annual data report: lung. Am J Transplant. 2021; 21(S2):441-520.
Reeb J, Keshavjee S, Cypel M. Expanding the lung donor pool: advancements and emerging pathways. Curr Opin Organ Transplant. 2015; 20(5):498-505.
Phillips KG, Ward AF, Ranganath NK, et al. Impact of the opioid epidemic on lung transplantation: donor, recipient, and discard characteristics. Ann Thorac Surg. 2019; 108(5):1464-1470.
Englum BR, Ganapathi AM, Speicher PJ, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant. 2016; 35(2):228-235.
Koenig A, Stepanova M, Saab S, Ahmed A, Wong R, Younossi ZM. Long-term outcomes of lung transplant recipients with hepatitis C infection: a retrospective study of the U.S. transplant registry. Aliment Pharmacol Ther. 2016; 44(3):271-278.
Aslam S, Grossi P, Schlendorf KH, et al. Utilization of hepatitis C virus-infected organ donors in cardiothoracic transplantation: an ISHLT expert consensus statement. J Heart Lung Transplant. 2020; 39(5):418-432.
Haji SA, Starling RC, Avery RK, et al. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant. 2004; 23(3):277-283.
Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006; 296(15):1843-1850.
Woolley AE, Singh SK, Goldberg HJ, et al. Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med. 2019; 380(17):1606-1617.
Cypel M, Feld JJ, Galasso M, et al. Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. Lancet Resp Med. 2020; 8(2):192-201.
Gidea CG, Narula N, Reyentovich A, et al. Increased early acute cellular rejection events in hepatitis C-positive heart transplantation. J Heart Lung Transplant. 2020; 39(11):1199-1207.
Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship?. Lancet Infect Dis. 2002; 2(9):539-549.
Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation. 2010; 89(8):1028-1033.
Peghin M, Los-Arcos I, Hirsch HH, et al. Community-acquired respiratory viruses are a risk factor for chronic lung allograft dysfunction. Clin Infect Dis. 2019; 69(7):1192-1197.
Smith DE, Chen S, Fargnoli A, et al. Impact of early initiation of direct-acting antiviral therapy in thoracic organ transplantation from hepatitis C virus positive donors. Semin Thorac Cardiovasc Surg. 2021; 33(2):407-415.
Lewis TC, Gidea C, Reyentovich A, et al. Management and tolerability of glecaprevir-pibrentasvir pharmacotherapy in hepatitis C viremic heart and lung transplant recipients. Clin Transplant. 2020; 34(10): e14030.
Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007; 26(12):1229-1242.
Husain AN, Siddiqui MT, Holmes EW, et al. Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 1999; 159(3):829-833.
Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2016; 35(4):397-406.
Todd JL, Neely ML, Kopetskie H, et al. Risk factors for acute rejection in the first year after lung transplant. A multicenter study. Am J Respir Crit Care Med. 2020; 202(4):576-585.
Angel LF, Levine DJ, Restrepo MI, et al. Impact of a lung transplantation donor-management protocol on lung donation and recipient outcomes. Am J Respir Crit Care Med. 2006; 174(6):710-716.
Chang SH, Kreisel D, Marklin GF, et al. Lung focused resuscitation at a specialized donor care facility improves lung procurement rates. Ann Thorac Surg. 2018; 105(5):1531-1536.
Li SS, Osho A, Moonsamy P, et al. Outcomes of lung transplantation from HCV viremic donors. Ann Thorac Surg. 2021. S0003-4975(21)00908-5. [online ahead of print].
Abdelbasit A, Hirji A, Halloran K, et al. Lung transplantation from hepatitis C viremic donors to uninfected recipients. Am J Respir Crit Care Med. 2018; 197(11):1492-1496.
Richter BI, Parent B, Lonze BE. The moral necessity to increase access to HCV+ transplants with early treatment for HCV naive patients. Transplantation. 2021. https://doi.org/10.1097/tp.0000000000003898. online ahead of print.
Feld JJ, Cypel M, Kumar D, et al. Short-course, direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: a phase 3, single-centre, open-label study. Lancet Gastroenterol Hepatol. 2020; 5(7):649-657.
Galasso M, Feld JJ, Watanabe Y, et al. Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion. Nature Commun. 2019; 10(1):481.
Bhorade SM, Husain AN, Liao C, et al. Interobserver variability in grading transbronchial lung biopsy specimens after lung transplantation. Chest. 2013; 143(6):1717-1724.
Stewart ZA, Stern J, Ali NM, et al. Clinical and financial implications of 2 treatment strategies for donor-derived hepatitis C infections. Transplant Direct. 2021; 7(10):e762.